publications-banner

Information about pipeline products

PublicationView

T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata H, Xu B, Kim S-B, et al.
Cancer Sci. 2024. doi: 10.1111/cas.16234.
Edoxaban
Cardiovascular - AF
R2-CHA2DS2-VASc score for cardiovascular event prediction after bioprosthetic valve replacement: Subanalysis from the BPV-AF registry
Sano M, Takegami M, Amano M, et al.
Circ Rep. 2024;6(8):341-348. doi: 10.1253/circrep.CR-24-0033.
Valemetostat
Lung Cancer
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer
Choudhury NJ, Lai WV, Makhnin A, et al.
Clin Cancer Res. 2024. doi: 10.1158/1078-0432.CCR-23-3383. Epub ahead of print.
Dato-DXd, DS-1103, Other/Multi
Other/Multi Tumor-agnostic
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
Sue M, Tsubaki T, Ishimoto Y, et al.
PLoS One. 2024;19(6):e0304985.
Edoxaban
Cardiovascular - AF
Application of the win ratio method in the ENGAGE AF-TIMI 48 trial comparing edoxaban with warfarin in patients with atrial fibrillation
Bergmark BA, Park J-G, Hamershock RA, et al.
Circ Cardiovasc Qual Outcomes. 2024;17(7):e010561.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial
Cortés J, Hurvitz SA, Im S-A et al.
Nat Med. 2024. doi: 10.1038/s41591-024-03021-7. Epub ahead of print.
Edoxaban
Cardiovascular - AF
Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer
Patell R, Hsu C, Shi M et al.
Haematologica. 2024;109(6):1849-1856.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer: A plain language summary of the DESTINY-Breast03 study
Cortés J
Future Oncol. 2023. doi: 10.2217/fon-2023-0422. Online ahead of print.
T-DXd
Breast Cancer
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Kapil A, Spitzmüller A, Brieu N, et al.
Sci Rep. 2024;14(1):12129
Other/Multi
Lung Cancer
Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: A review
Kurzrock R, Chaudhuri AA, Feller-Kopman D, et al.
Cancer Metastasis Rev. 2024. doi: 10.1007/s10555-024-10187-6. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer